



1500 Fannie Dorsey Rd. Sykesville, MD 20797
Phone: 301-529-3825 | www.otraces.com

FOR IMMEDIATE RELEASE

MEDIA CONTACT:

Nancy Rose Senich
nancy@rose4results.com
202.262.6996 cell/txt

Beyond Liquid Biopsy ---- OTraces Accesses the Tumor Microenvironment (TME) in Its Cancer Blood-Based Test to Advance Detection and Diagnosis (White Paper)

OTraces' R&D Team Issues White Paper Outlining Initial Validation Trial Results of Its Math- and Physics-Based Diagnostics Platform That Can Boost Biomarker Accuracy and Performance

Sykesville, Maryland (June 12, 2017) -- [OTraces Inc.](http://OTraces.com), a biotech company developing blood tests for cancer diagnosis, announces the development of the first blood test modality to access the diagnostic content of the Tumor Microenvironment (TME). The TME is widely regarded as a storehouse of patient status information that far exceeds the tumor itself or known capabilities of DNA testing.

OTraces has issued a white paper available for download from their website www.otraces.com (see press releases).

"OTraces is currently engaged in validation trials, including one for prostate cancer at Johns Hopkins University Medical Center under the direction of Dr. Kenneth Pienta, who is a world authority on prostate cancer research and a widely-quoted expert on the TME," said Keith Lingenfelter, OTraces' Chief Executive Officer. "This test could save time, money, improve patient outcomes and, most importantly, save lives."

OTraces White Paper describes this technology in detail, the technology encompasses:

- 1) Accessing the diagnostic information that resides in the "Tumor Microenvironment (TME)", the cellular structures and fluids that surround a cancer tumor and which recent research has indicated is a vast storehouse of tumor activity information that far exceeds tumor markers or the DNA isolated in circulating cancer tumor cells (CTCs) as utilized by liquid biopsy;
- 2) Math- and physics-based noise suppression technology that enhances diagnostic accuracy by reducing "proteomic noise" — a longstanding problem that continues to plague the industry and that OTraces has largely resolved as evidenced by validation trials for both prostate and breast cancer where their tests have averaged 90%+ accuracy as determined by predictive power, considered one of the most demanding performance standards in the industry. This compares favorably with an estimated current industry average of 70-75% predictive power for most other tests;
- 3) Technology resides in biomarker-agnostic, cloud-based software that will be available via the web for in vitro cancer and disease diagnosis for physicians, laboratories and companies worldwide seeking biomarker optimization through collaboration with OTraces. Possibilities range from multiple currently marketed CLIA lab tests in the U.S. to a urine based screen for

cancer in the Far East.

The advantages of using the OTraces TME-based approach to cancer screening relative to DNA-based liquid biopsy and other known modalities include:

- Definitive determination of whether cancer is present or not.
- Differentiation between aggressive and non-aggressive tumors.
- Determination of cancer stage and tracking cancer progression.
- Lower Cost per test (estimated to be less than \$100 each).

For more information, please visit www.OTraces.com or email Sales@OTraces.com.

About OTraces Inc.

Founded in OTraces, Inc. (www.OTraces.com) is a privately-held biotech company based in Sykesville, MD, that provides advanced oncology diagnostic systems. It has developed a protein-based technology (proteomics) for detecting cancers with simple blood tests. OTraces is currently planning to raise \$6 million in a preferred stock offering to complete prostate cancer validation trials in the U.S. and to advance commercialization of its breast cancer test abroad. Unlike players in the liquid biopsy field, OTraces' software is extensively patented, biomarker-agnostic, cloud-based and management believes the company's tests offer a range of clinical and cost advantages with respect to global screening criteria.

Investor Inquiries:

Keith Lingenfelter

CEO and Chairman

OTraces Inc.

(301) 529 3824